STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRK
  4. [Form 4] Merck & Co., Inc. Insider Trading Activity

Merck (NYSE: MRK) EVP exercises stock options and sells 18,706 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Merck & Co., Inc. executive David R. Maraldo, EVP & President Merck Manufacturing Division, reported exercising stock options for a total of 18,706 shares of common stock on August 5, 2026, at exercise prices of $73.73, $87.10, and $84.71 per share. He then sold the resulting 18,706 shares in open-market transactions at a weighted average price of $128.7179 per share, with sale prices ranging from $128.64 to $128.85 per share.

Positive

  • None.

Negative

  • None.
Insider Maraldo David R.
Role EVP & Pres. MMD
Sold 18,706 shs ($2.41M)
Approx. gross sale proceeds $2.41M
Approx. exercise cost $1.54M
Approx. pre-tax spread $869K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F2 6,311 $0.00 $0.00
Exercise Stock Option (Right to Buy) F3 9,709 $0.00 $0.00
Exercise Stock Option (Right to Buy) F4 2,686 $0.00 $0.00
Exercise Common Stock 6,311 $73.73 $465K
Sale Common Stock F1 6,311 $128.7179 $812K
Exercise Common Stock 9,709 $87.10 $846K
Sale Common Stock F1 9,709 $128.7179 $1.25M
Exercise Common Stock 2,686 $84.71 $228K
Sale Common Stock F1 2,686 $128.7179 $346K
Holdings After Transaction: Stock Option (Right to Buy) — 8,528 shares (Direct); Common Stock — 18,212.434 shares (Direct)
Footnotes (4)
  1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote.
  2. F2. The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024.
  3. F3. The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025.
  4. F4. The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
Shares sold 18,706 shares Total Merck common stock sold on 2026-08-05 by David R. Maraldo
Weighted average sale price $128.7179 per share Weighted average for sales on 2026-08-05; trades ranged $128.64–$128.85
Option exercise price $73.73 per share Exercise price for 6,311 stock options exercised on 2026-08-05
Option exercise price $87.10 per share Exercise price for 9,709 stock options exercised on 2026-08-05
Option exercise price $84.71 per share Exercise price for 2,686 stock options exercised on 2026-08-05
Options exercised 18,706 options Total stock options (rights to buy) exercised on 2026-08-05
Stock Option (Right to Buy) financial
"security title is listed as "Stock Option (Right to Buy)""
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vested and became exercisable financial
"The option vested and became exercisable in three equal installments on 5/4/2022"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did MRK executive David R. Maraldo report?
David R. Maraldo reported exercising stock options for 18,706 shares of Merck common stock and selling all 18,706 shares on August 5, 2026. The transactions combined option exercises with same-day open-market sales.

How many Merck (MRK) shares did David R. Maraldo sell and at what price?
He sold 18,706 shares of Merck common stock at a weighted average price of $128.7179 per share. A footnote states the individual trades occurred between $128.64 and $128.85 per share on August 5, 2026.

What option exercise prices were involved in David R. Maraldo’s MRK Form 4?
He exercised three stock option grants covering 6,311 shares at $73.73, 9,709 shares at $87.10, and 2,686 shares at $84.71 per share. Each exercise converted options into an equal number of Merck common shares before their sale.

Were David R. Maraldo’s MRK sales reported as open-market transactions?
Yes. The Form 4 uses transaction code S, described as a sale in an open market or private transaction. A footnote further explains that the reported price is a weighted average across multiple trades within a stated price range.

Does the MRK Form 4 indicate a Rule 10b5-1 trading plan for these transactions?
The filing’s Rule 10b5-1 checkbox is not marked as affirmatively adopted. There is no footnote stating that the August 5, 2026 transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maraldo David R.
(Last)(First)(Middle)
126 EAST LINCOLN AVENUE
(Street)
RAHWAY NEW JERSEY 07065
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & Pres. MMD
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/05/2026M6,311A$73.7324,523.434D
Common Stock08/05/2026S6,311D$128.7179(1)18,212.434D
Common Stock08/05/2026M9,709A$87.127,921.434D
Common Stock08/05/2026S9,709D$128.7179(1)18,212.434D
Common Stock08/05/2026M2,686A$84.7120,898.434D
Common Stock08/05/2026S2,686D$128.7179(1)18,212.434D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$73.7308/05/2026M6,31105/04/2022(2)05/03/2031Common Stock6,311$03,154D
Stock Option (Right to Buy)$87.108/05/2026M9,70905/03/2023(3)05/02/2032Common Stock9,709$00D
Stock Option (Right to Buy)$84.7108/05/2026M2,68604/29/2026(4)04/28/2035Common Stock2,686$05,374D
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote.
2. The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024.
3. The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025.
4. The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
/s/ Kelly E. W. Grez as Attorney-in-Fact for David R. Maraldo08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR